Review and clinical update on parenteral nutrition-associated liver disease

Research output: Contribution to journalReview article

50 Citations (Scopus)

Abstract

Parenteral nutrition-associated liver disease (PNALD) is a complex disease that is diagnosed by clinical presentation, biochemical markers of liver injury, concurrent use of parenteral nutrition (PN), and negative workup for other causes of liver disease. Since the first case of PNALD was reported more than 30 years ago, clinicians have had few effective treatments for PNALD, and when disease progressed to liver cirrhosis, it was historically associated with poor outcomes. Within the past 5 years, there has been much excitement about new treatments for PNALD, including use of both parenteral and enteral ω-3 polyunsaturated long-chain fatty acids (ω-3 PUFA) as well as restricting dosing of ω-6 PUFA. Scientists are also interested in uncovering the mechanisms associated with liver injury seen in PNALD. This article reviews the recent literature relating to the pathophysiology and treatment of PNALD.

Original languageEnglish (US)
Pages (from-to)30-39
Number of pages10
JournalNutrition in Clinical Practice
Volume28
Issue number1
DOIs
StatePublished - Feb 1 2013
Externally publishedYes

Fingerprint

Parenteral Nutrition
Liver Diseases
Liver
Wounds and Injuries
Liver Cirrhosis
Small Intestine
Fatty Acids
Therapeutics
Biomarkers

Keywords

  • cholestasis
  • fat emulsions, intravenous
  • fatty acids, omega-3
  • fatty acids, omega-6
  • parenteral nutrition
  • parenteral nutrition, home

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

Review and clinical update on parenteral nutrition-associated liver disease. / Tillman, Emma.

In: Nutrition in Clinical Practice, Vol. 28, No. 1, 01.02.2013, p. 30-39.

Research output: Contribution to journalReview article

@article{fe991151e4a34e6db335834139bac349,
title = "Review and clinical update on parenteral nutrition-associated liver disease",
abstract = "Parenteral nutrition-associated liver disease (PNALD) is a complex disease that is diagnosed by clinical presentation, biochemical markers of liver injury, concurrent use of parenteral nutrition (PN), and negative workup for other causes of liver disease. Since the first case of PNALD was reported more than 30 years ago, clinicians have had few effective treatments for PNALD, and when disease progressed to liver cirrhosis, it was historically associated with poor outcomes. Within the past 5 years, there has been much excitement about new treatments for PNALD, including use of both parenteral and enteral ω-3 polyunsaturated long-chain fatty acids (ω-3 PUFA) as well as restricting dosing of ω-6 PUFA. Scientists are also interested in uncovering the mechanisms associated with liver injury seen in PNALD. This article reviews the recent literature relating to the pathophysiology and treatment of PNALD.",
keywords = "cholestasis, fat emulsions, intravenous, fatty acids, omega-3, fatty acids, omega-6, parenteral nutrition, parenteral nutrition, home",
author = "Emma Tillman",
year = "2013",
month = "2",
day = "1",
doi = "10.1177/0884533612462900",
language = "English (US)",
volume = "28",
pages = "30--39",
journal = "Nutrition in Clinical Practice",
issn = "0884-5336",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Review and clinical update on parenteral nutrition-associated liver disease

AU - Tillman, Emma

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Parenteral nutrition-associated liver disease (PNALD) is a complex disease that is diagnosed by clinical presentation, biochemical markers of liver injury, concurrent use of parenteral nutrition (PN), and negative workup for other causes of liver disease. Since the first case of PNALD was reported more than 30 years ago, clinicians have had few effective treatments for PNALD, and when disease progressed to liver cirrhosis, it was historically associated with poor outcomes. Within the past 5 years, there has been much excitement about new treatments for PNALD, including use of both parenteral and enteral ω-3 polyunsaturated long-chain fatty acids (ω-3 PUFA) as well as restricting dosing of ω-6 PUFA. Scientists are also interested in uncovering the mechanisms associated with liver injury seen in PNALD. This article reviews the recent literature relating to the pathophysiology and treatment of PNALD.

AB - Parenteral nutrition-associated liver disease (PNALD) is a complex disease that is diagnosed by clinical presentation, biochemical markers of liver injury, concurrent use of parenteral nutrition (PN), and negative workup for other causes of liver disease. Since the first case of PNALD was reported more than 30 years ago, clinicians have had few effective treatments for PNALD, and when disease progressed to liver cirrhosis, it was historically associated with poor outcomes. Within the past 5 years, there has been much excitement about new treatments for PNALD, including use of both parenteral and enteral ω-3 polyunsaturated long-chain fatty acids (ω-3 PUFA) as well as restricting dosing of ω-6 PUFA. Scientists are also interested in uncovering the mechanisms associated with liver injury seen in PNALD. This article reviews the recent literature relating to the pathophysiology and treatment of PNALD.

KW - cholestasis

KW - fat emulsions, intravenous

KW - fatty acids, omega-3

KW - fatty acids, omega-6

KW - parenteral nutrition

KW - parenteral nutrition, home

UR - http://www.scopus.com/inward/record.url?scp=84872380359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872380359&partnerID=8YFLogxK

U2 - 10.1177/0884533612462900

DO - 10.1177/0884533612462900

M3 - Review article

VL - 28

SP - 30

EP - 39

JO - Nutrition in Clinical Practice

JF - Nutrition in Clinical Practice

SN - 0884-5336

IS - 1

ER -